Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Katherine Gano"'
Autor:
Andrea E Wahner Hendrickson, Nathan Foster, Bradley R Corr, Linda Duska, Merry J Markham, Kristina Butler, Eugenia Girda, Rachel Ware Miller, Katherine Arneson, Katherine Gano, Janelle Johnson, Geoffrey Shapiro, Larry Rubinstein, S Percy Ivy, Elise Kohn, Alex Adjei, Scott Kaufmann
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c4d408cdf1fa53ea53b701af814985e
https://doi.org/10.1136/ijgc-2022-esgo.512
https://doi.org/10.1136/ijgc-2022-esgo.512
Autor:
Thomas M. Habermann, Brenda Ginos, Jose F. Leis, Craig B. Reeder, Talal Hilal, Allison C. Rosenthal, Katherine Gano, Christopher R. Conley, Stephen M. Ansell, Mohamad Bassam Sonbol, Peter Leif Bergsagel, Donald W. Northfelt, Amylou C. Dueck, Heidi E. Kosiorek, Craig Nichols, Thomas E. Witzig, Patrick B. Johnston, David J. Inwards
Publikováno v:
Leukemia & Lymphoma. 59:2128-2134
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexame
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae7571562ceb93003ad89184ae62f21
https://doi.org/10.1080/10428194.2017.1416368
https://doi.org/10.1080/10428194.2017.1416368
Autor:
Raoul Tibes, John Mascarenhas, Craig B. Reeder, Jeanne Palmer, Krisstina L. Gowin, Ruben A. Mesa, Katherine Gano, Heidi E. Kosiorek, John K. Camoriano, Amylou C. Dueck, Ronald Hoffman
Publikováno v:
Leukemia Research. 60:31-35
Myelofibrosis is a myeloproliferative neoplasm that is characterized by splenomegaly, profound symptom burden, and cytopenias. JAK inhibitor therapy offers improvements in splenomegaly, symptom burden, and potentially survival; however, cytopenias re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b38a2de3d76a3301ead3f639e902551
https://doi.org/10.1016/j.leukres.2017.06.005
https://doi.org/10.1016/j.leukres.2017.06.005
Autor:
Biswajit Das, Geoffrey I. Shapiro, Suzanne George, Mahesh Seetharam, Jacob B. Allred, James L. Chen, Sosipatros A. Boikos, Premal H. Thaker, Bose Kochupurakkal, Melissa Amber Burgess, Katherine Gano, Yves Pommier, Nam Bui, S. Percy Ivy, Steven Attia, Gary K. Schwartz, Matthew Ingham, Jane B. Trepel, Julia Close, Gregory M. Cote
Publikováno v:
Journal of Clinical Oncology. 38:TPS11570-TPS11570
11506 Background: Uterine leiomyosarcoma (uLMS) is an aggressive sarcoma subtype with frequent metastatic relapse. After failure of front-line chemotherapy, remaining options provide limited benefit (trabectedin: ORR 11%, mPFS 4.0 mos; pazopanib: ORR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5555e1dde35bacfdf2190f02b0cc7583
https://doi.org/10.1200/jco.2020.38.15_suppl.tps11570
https://doi.org/10.1200/jco.2020.38.15_suppl.tps11570
Autor:
Allison C. Rosenthal, Katherine Gano, Amylou C. Dueck, A. Keith Stewart, Jacob P. Laubach, Ravi Vij, Shaji Kumar, Craig C. Hofmeister
Publikováno v:
British Journal of Haematology. 174:323-325
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a806a063f17e0b2db49b69042a31d1a9
https://doi.org/10.1111/bjh.13765
https://doi.org/10.1111/bjh.13765
Autor:
Rodger E. Tiedemann, Pierre Noel, David Dingli, A. Keith Stewart, Allison C. Rosenthal, Shaji Kumar, Morie A. Gertz, Joseph R. Mikhael, Rafael Fonseca, Christopher R. Conley, Grzegorz S. Nowakowski, Stephen M. Ansell, Prashant Kapoor, John K. Camoriano, Nelson Leung, Luis F. Porrata, Jose F. Leis, Katherine Gano, Francis K. Buadi, David J. Inwards, Amylou C. Dueck, Joseph P. Colgan, Thomas M. Habermann, Thomas E. Witzig, Stephen J. Russell, Craig B. Reeder
Publikováno v:
American journal of hematology. 92(5)
Patients with indolent non-Hodgkin lymphoma (NHL) have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in relapsed lymphoma. This trial was conduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253836eeb58aceb57946e9a315aa1cd7
https://pubmed.ncbi.nlm.nih.gov/28230270
https://pubmed.ncbi.nlm.nih.gov/28230270
Autor:
P. Leif Bergsagel, Craig B. Reeder, Amylou C. Dueck, Edward N. Libby, Sravan K. Nagi Reddy, Angela Mayo, A. Keith Stewart, Luciano J. Costa, Joseph R. Mikhael, Katherine Gano, Francis K. Buadi
Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1-28) and 40 mg dexamethasone (days 1, 8, 15,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aedf87f18773efb8bb044c78c95a3c9
https://europepmc.org/articles/PMC4521972/
https://europepmc.org/articles/PMC4521972/
Autor:
Allison C. Rosenthal, David Dingli, Morie A. Gertz, Thomas E. Witzig, Shaji Kumar, Francis K. Buadi, John K. Camoriano, Christopher R. Conley, Jose F. Leis, Craig B. Reeder, Thomas M. Habermann, Stephen M. Ansell, Rodger E. Tiedemann, James L. Slack, Amylou C. Dueck, Riccardo Valdez, Pierre Noel, Grzegorz S. Nowakowski, Joseph R. Mikhael, Stephen J. Russell, Kelly K. Curtis, A. Keith Stewart, Nelson Leung, Rafael Fonseca, David J. Inwards, Prashant Kapoor, Katherine Gano, Joseph P. Colgan, Luis F. Porrata
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:S225-S226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b46b723872e2ffce493eb88dedf3ee4a
https://doi.org/10.1016/j.clml.2015.04.104
https://doi.org/10.1016/j.clml.2015.04.104
Autor:
Vineta Ghurye, Amylou C. Dueck, Katherine Gano, Patricia A. Koenig, Heidi E. Kosiorek, Veena Fauble, Krisstina L. Gowin, Craig B. Reeder, Ronald Hoffman, John K. Camoriano, Raoul Tibes, John Mascarenhas, Ruben A. Mesa
Publikováno v:
Blood. 126:1618-1618
Introduction: Most myelofibrosis (MF) patients develop anemia during evolution of the disease process predicting decreased survival. Previous studies exploring the effect of danazol for the treatment of anemia in MF demonstrate responses in anemia. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd4b93c028aef0dcb055fe987c9a9c75
https://doi.org/10.1182/blood.v126.23.1618.1618
https://doi.org/10.1182/blood.v126.23.1618.1618
Autor:
Allison C. Rosenthal, Craig B. Reeder, Amylou C. Dueck, Thomas M. Habermann, Angela Toro, Sravan K. Nagi Reddy, Patrick B. Johnston, Craig Nichols, Donald W. Northfelt, Jose F. Leis, Thomas E. Witzig, Daniel J. Johnson, Katherine Gano, James L. Slack, P. Leif Bergsagel, Rodger E. Tiedemann
Publikováno v:
Blood. 124:4410-4410
Introduction Non-Hodgkin lymphoma responds to single agents such as cyclophosphamide, combination therapy such as CVP and immunotherapy with monoclonal antibodies such as rituximab. There is no consensus on the optimal treatment for relapsed low grad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d0bddb73462bba9fa479f4600c0adf
https://doi.org/10.1182/blood.v124.21.4410.4410
https://doi.org/10.1182/blood.v124.21.4410.4410